---
title: Oncologic Medications
author: J. Austin Straley, DO
layout: post
chapter: 9
section: 01
lesson: 34
date: 2023-03-30
---

- General
  - New Afib in cancer patients is associated with increased risk of HF and VTW
- Common Groups
  - ABVD
    - Adriamycin, Bleomycin, Vinblastine, Dacarbazine
    - Hodgkin Lymphoma
  - BEACOPP
    - Bleomycin, Etoposide, Adriamycin/doxorubicin, Cyclophosphamide, Oncovorin/vincristine, Procarbazine, Prednisone
    - Hodgkin Lymphoma
  - FOLFOX
    - Leucovorin, Fluorouracil, Oxaliplatin
  - R-CHOP
    - Rituximab, Cyclophosphamide, Hydroxy-doxorubicin, Oncovorin/Vincristine, Prednisone
- Cancer-related Cachexia
  - Hypercatabolic state characterized by appetite and weight loss with a disproportionate loss of skeletal muscle
  - Treatment
    - Progesterone analogs (Megestrol acetate, Medroxyprogesterone) and corticosteroids (Dexamethasone)
      - PAs preferred in pts with longer life expectancies
- 5-Fluorouracil (5-FU)
  - MOA: Direct Inhibitor of pyrimidine synthesis (blocks thymidylate synthase), thereby blocking protein and DNA synthesis
    - Leucovorin increases 5-FU effectiveness
  - Anti-metabolite
    - Inflammation resolves about 2 weeks after treatment discontinuation
  - SE: Myelosuppression and Photosensitivity, Palmar-plant erythrodysesthesia (hand-foot syndrome), cerebellar toxicity
- 6-Mercaptopurine (6-MP)
  - Anti-metabolite, metabolized by xanthine oxidase (inhibited by allopurinol)
    - Side effects are worse when on allopurinol (stop or reduce)
    - Thiopurine
  - SE: Myelosuppressive, Hepatotoxic, Interacts with allopurinol
  - Azathioprine
    - Converted to 6-MU and also metabolized by xanthine oxidase, also interacts with allopurinol
- Alemtuzumab (Lemtrada)
  - Anti-CD52
  - Use: CLL, MS
- All-Trans Retinoic Acid (ATRA)
  - MOA: Inhibits transcriptional repression by PML-RARa
  - Tretinoin
  - Formulation of Vitamin A, targeted therapy for Acute Promyelocytic Leukemia (M3 variant)
    - Causes immature myeloblasts to differentiate into mature myelocytes
  - Combined with an Anthracycline (Daunorubicin, Idarubicin) for best results
  - SE: Rashes, Teratogenic, DIC
- Aromatase Inhibitors
  - Anastrozole, letrozole, and vorozole
  - Block formation of new estrogen (good for metastatic disease)
  - Give Calcium and Vitamin D supplements, Get DEXA
    - Bisphosphonates or denosumab if osteoporotic
  - Increased risk of osteoporosis and fracture
  - SE: Arthralgia, joint stiffness and bone pain in 33%, Vaginal dryness, sexual dysfunction, CV events, hyperlipidemia, and higher risks of osteoporosis and fractures
- Axitinib (Inlyta)
  - Use: RCC
- Bevacizumab (Avastin)
  - Anti-VEGF
  - Use: Colorectal cancer, renal cell carcinoma, non-small cell lung cancer
  - SE: PRES syndrome
- Bleomycin
  - Antitumor antibiotic used in testicular cancer and Hodgkin's Lymphoma
  - No myelosuppression (vs. Busulfan)
    - Induces free radical formation and cause breaks in DNA
  - SE: Severe Pulmonary Fibrosis, Fever, and hypersensitivity
- Bortezomib (Velcade)
  - MOA: Proteasome inhibitor
  - SE: Peripheral Neuropathy, Herpes Reactivation
    - Prophylactic acyclovir or valacyclovir
- Busulfan
  - Alkylates DNA
  - Pulmonary Fibrosis and myelosuppression
- Capecitabine (Xeloda)
  - Adjuvant for colon cancer
  - SE: Palmar-plant erythrodysesthesia (hand-foot syndrome)
- Caplacizumab (Cablivi)
  - Monoclonal antibody
  - Use: Severe TTP
- Cetuximab (Erbitux)
  - Anti-EGFR
  - Stage IV colorectal cancer, head and neck cancers
  - SE: Pustular acneiform eruptions (severe), pulmonary toxicity
- Chemotherapy-Induced Cardiotoxicity
  - Type I
    - Associated with Anthracyclines
      - Daunorubicin
      - Doxorubicin (Adriamycin, Doxil)
      - Idarubicin
      - Generate free radicals to intercalate DNA
        - Causes severe tissue necrosis
    - Myocyte Necrosis and destruction w/fibrosis
      - Progression to overt clinical heart failure
      - Less likely to be reversible
    - SE: Dilated Cardiomyopathy with chronic use
      - Antitumor Antibiotic, myelosuppression, alopecia, severe gastric upset secondary to colonic mucositis
      - Total cumulative dose is most strongly related to risk
    - Antidote is Dexrazoxane
      - Iron-chelating agent used for cardiac protection
  - Type II
    - Associated with Trastuzumab
    - Myocardial stunning/hibernation w/o myocyte destruction
    - Asymptomatic LV systolic dysfunction
    - More likely to be reversible
- Cyclophosphamide (Cytoxan)
  - Covalently links DNA at guanine N-7
  - SE: Hemorrhagic Cystitis, SIADH (hyponatremia), bladder carcinoma, myelosuppression, sterility (acrolein, metabolite causes all the damage)
    - Cystitis can be treated with 2-Mercaptoethanesulfonate (Mensa) which binds the metabolite acrolein (bladder irritant), fluids
    - Alkylating agents put patient at risk for developing secondary cancer (Acute Leukemia)
- Dactinomycin
  - Intercalates DNA
  - Used in Wilms' Tumor, Ewing Sarcoma, Rhabdomyosarcoma
- Dasatinib (Sprycel)
  - Tyrosine Kinase Inhibitor
  - Used in CML
  - SE: pulmonary hypertension
- Daunorubicin (Cerubidine)
  - Anthracyclines
  - Generate free radicals to intercalate DNA
    - Causes severe tissue necrosis
  - SE: Dilated Cardiomyopathy with chronic use, Mucositis, stomatitis
    - Antitumor Antibiotic, myelosuppression, alopecia, severe gastric upset secondary to colonic mucositis
    - Total cumulative dose is most strongly related to risk
  - Antidote is Dexrazoxane
    - Iron-chelating agent used for cardiac protection
- Doxorubicin (Hydroxydaunomycin)
  - SE: Mucositis, stomatitis
- Eculizumab
  - MOA: Monoclonal antibody against C5, blocks cleavage and blocks formation of the C5-9 complex
    - Used in Paroxysmal nocturnal hemoglobinuria
- Elotuzumab
  - MOA: Activating NK cells to kill MM cells, Targets SLAMF7
- Erlotinib
  - SE: Pustular acneiform eruptions (weak), pulmonary toxicity
- Folinic Acid (Leucovorin)
- Gefitinib
  - SE: Pustular acneiform eruptions (weak)
- Hydroxyurea
  - MOA: Inhibits ribonucleotide reductase, decreasing DNA synthesis
  - Use: Essential Thrombocytopenia, PCV
- Ibrutinib (Imbruvica)
  - Tyrosine Kinase Inhibitor, binds BTK
  - Metabolized by CYP3A4
    - Increases digoxin levels
  - Use: CLL, B-cell Lymphoma
  - SE: Increased rates of Atrial Fibrillation (up to 16%) â€“ Don't use CCBs
- Imatinib (Gleevec)
  - MOA: Blocks ATP binding to tyrosine kinase active site
  - Use: CML, GIST
    - Blocks BCR-ABL fusion
  - Can be held without significant change in labs, may hold for entire pregnancy without problems
  - SE: Nausea
- Ifosfamide
  - SE: hemorrhagic cystitis
- Lenalidomide (Revlimid)
- Methotrexate
  - MOA: Folate Antagonist (Dihydrofolate Reductase Inhibitor)
    - Converts oxidized folate back into its reduced form to be used in pyrimidine synthesis
      - Can be bypassed/fixed by Leucovorin (N5-formyltetrahydrofolate)
    - used in Rheumatoid Arthritis also
    - Stops DNA and protein synthesis hindering S-phase
  - SE: Myelosuppression and Abortifacient, Hepatotoxicity, stomatitis, cytopenia
- Microtubule Inhibitors
  - Taxols/Taxanes
    - MOA: Inhibit microtubule degradation
      - Bind polymerized microtubules and stabilize the mitotic spindle so it can not break down
      - Inhibiting dynein
      - Cell phase: M phase
    - SE: Some myelosuppression
    - Paclitaxel (Taxol)
      - Nab-paclitaxel (Abraxane)
    - Docetaxel (Taxotere)
  - Vinca Alkaloids
    - MOA: Inhibits microtubule production and assembly
      - Bind B-tubulin and block polymerization, therefore the mitotic spindle cannot form
      - Inhibit kinesin
      - Cell phase: M phase
    - Use: Hematologic and solid malignancies
    - SE: Alopecia, Paralytic ileus/constipation
    - Vincristine:
      - Use: Non-Hodgkin
      - SE: Peripheral Neuropathies (Neurotoxic), Alopecia
        - Stocking and glove distribution
        - Areflexia, peripheral neuritis, motor symptoms less commonly
        - Autonomic dysfunction
        - Paralytic ileus/constipation
        - Some myelosuppression usually mild
    - Vinblastine
      - Use: Hodgkin
      - SE: Profound Bone Marrow Suppression, Alopecia
- Mitomycin
  - Antitumor Antibiotic
  - SE: Hemolytic Uremic Syndrome
- Nilotinib
  - SE: Coronary insufficiency
- Nitrosoureas

    - Can cross BBB to treat brain cancer
    - SE: pulmonary fibrosis
  - Carmustine
  - Lomustine
  - Semustine
  - Streptozocin
- Panitumumab (Vectibix)
  - SE: Pustular acneiform eruptions (severe)
- Platinum Drugs
  - General
    - Prevent nephrotoxicity with Amifostine
    - Magnesium wasting (hypomagnesemia)
  - Carboplatin
    - Platinum Alkylating Agent
      - Hydrate well to protect the kidneys, highly emetogenic (give something for vomiting)
    - SE: Myelosuppression is main/dose limiting SE
      - Less other SE than Cisplatin
        - Ototoxicity and Nephrotoxicity
        - Less nephrotoxic than Cisplatin
  - Cisplatin
    - Platinum Alkylating Agent
      - Prevents replication of tumor cells by causing intra-stand links within DNA
    - SE: Myelosuppression, Peripheral Neuropathies (stocking glove), Nephrotoxic (ATN), Ototoxic, electrolyte abnormalities, Tinnitus, N/V
      - Less nephrotoxic with aggressive hydration
  - Oxaliplatin
    - SE: Peripheral Neuropathies (stocking glove), transient cold hypersensitivity
      - No cold items for several days after infusions
- Ponatinib
  - SE: Coronary insufficiency
- Purine Analogs

    - MOA: Cytotoxic purine analog
      - Inhibits DNA polymerase Alpha and Beta
    - SE: Immunosuppression
  - Cladribine/Pentostatin
    - Used in symptomatic hairy cell leukemias
- Pyrimidine Analogs

    - MOA: Cytotoxic pyrimidine analog
      - Inhibits DNA polymerase Alpha and Beta
    - SE: Immunosuppression/Myelosuppression
  - Gemcitabine (Gemzar)
    - Used in hematologic and solid tumors, small-cell
    - SE: Severe Pulmonary Fibrosis, Hemolytic Uremic Syndrome
  - Cytarabine (Ara-C)
    - Aka Arabinofuranosyl Cytidine
    - Used in Non-M3 AML, non-Hodgkin Lymphoma hematologic cancers only
    - Cell Cycle: S phase
    - SE: Megaloblastic Macrocytic anemia, cerebellar toxicity
- Radiation
  - MOA: Damages DNA, preventing tumor cell division or directly killing the cells
    - Can decrease the tumor size or kill any existing tumor cells
  - SE: Slower wound healing, fibrosis, ulcerations, strictures, irritation, neurologic deficits, BM suppression, 2ndary cancers (sarcomas, thyroid cancer, CML)
  - Goals: First line in some tumors
    - Eradicate smaller tumors
    - Sensitize cancer cells to radiation therapy
- Selective Estrogen Receptor Antagonist (SERM)
  - Tamoxifen
    - Antagonist in the breasts, Agonist in the Endometrium and bone
    - SE: Deep Venous Thrombosis (DVT), hot flashes, endometrial cancer risk, teratogenic
  - Raloxifene
    - Antagonist in the breasts and endometrium, agonist in bone (osteoporosis treatment)
    - No increased risk for cancer
    - SE: Deep Venous Thrombosis (DVT), hot flashes
- Sunitinib (Sutent)
  - SE: PRES syndroms
- Thalidomide (Thalomid)
- Topoisomerase Inhibitors
  - Cell Cycles affected: S, G2
  - MOA: Eukaryotic Topoisomerase I Inhibitors
    - Topotecan
      - Used in ovarian and small cell lung cancer
    - Irinotecan
      - Used in Colon cancer
    - SE: Severe/Life-threatening Diarrhea
  - MOA: Eukaryotic Topoisomerase II Inhibitors
    - Etoposide
    - Teniposide
    - Inhibits relegation of double strand breaks caused by topoisomerase II
    - Used in a regimen with bleomycin and cisplatin for testicular masses, small cell lung cancer, Hodgkin and non-Hodgkin Lymphoma
    - SE: Alopecia, myelosuppression, Immunosuppression
- Trastuzumab
  - MOA: Anti-HER2/neu antibody
    - Binds HER2 on tumor surface and induces receptor internalization
  - Use: HER2 (+) Breast cancer, Gastric cancer
  - SE: Type II Cardiotoxicity, pulmonary toxicity, oligohydramnios
    - Avoid pregnancy for 7 months last dose
- Tretinoin
  - Formulation of Vitamin A, targeted therapy for Acute Promyelocytic Leukemia (M3 variant)
  - SE: Rashes, Teratogenic
- Vincristine (Oncovorin)